Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

Recent & Breaking News (TSX:VRX)

Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance

PR Newswire January 30, 2017

JJ Kinahan Walks Us Through The Most Traded Stocks Among TDA Clients In 2016: Apple, Bank of America & More

Benzinga.com  January 27, 2017

Options Trades for Alibaba, Salesforce, ArcelorMittal, Valeant Pharmaceuticals, and Verizon Communications Released by InvestorsObserver

PR Newswire January 26, 2017

Alan Knuckman's Bullish Valeant Trade

Benzinga.com  January 25, 2017

Healthcare Stocks Under Scanner -- Valeant Pharma, Alkermes, Universal Health Services, and LifePoint Health

PR Newswire January 13, 2017

Trump: Drug Industry Is 'Getting Away With Murder'

Benzinga.com  January 11, 2017

Valeant Takes First Steps To De-Leverage Its Balance Sheet, Challenges Remain

Benzinga.com  January 11, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  January 10, 2017

Valeant's Asset Sale To L'Oreal Explained

Benzinga.com  January 10, 2017

Valeant's Laundry List: Products, Divestitures And Debt Load

Benzinga.com  January 10, 2017

New Valeant = Old Valeant: Wells Fargo

Benzinga.com  January 10, 2017

20 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  January 10, 2017

A Peek Into The Markets: U.S. Stock Futures Mostly Flat Ahead Of Wholesale Inventories Report

Benzinga.com  January 10, 2017

Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118

PR Newswire January 10, 2017

Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses

PR Newswire January 10, 2017

Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion

PR Newswire January 10, 2017

Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash

PR Newswire January 9, 2017

Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

PR Newswire January 4, 2017

Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors

PR Newswire January 4, 2017

A Look Back At Valeant's Tumultuous 2016

Benzinga.com  December 18, 2016